|
Post by eddiemoy on Jun 1, 2015 18:59:00 GMT -5
isn't afrezza cheaper than the alternative? from the script data screen shots looks that way...
|
|
|
Post by nylefty on Jun 1, 2015 19:55:25 GMT -5
How do you all interpret "by 2017"... by 1/1/17 or sometime in 2017... personally that means to me before 1/1/17.. just curious or maybe i'm being to literal. I took it to mean sometime in 2017. Otherwise (I would think) he would have said by the end of 2016. $37 anytime in 2017 would be fine with me.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 1, 2015 20:10:54 GMT -5
isn't afrezza cheaper than the alternative? from the script data screen shots looks that way... Depends on how you define cheaper
|
|
|
Post by tigiron on Jun 1, 2015 20:22:48 GMT -5
I believe almost all investors would be smiling if $37/share target be reached by END of 2017. Does anyone have full report? I could not find the time frame (2017) for the $37 to be attained, not in those news articles --- there are a few places that were vague, maybe intentionally so.
|
|
|
Post by gamblerjag on Jun 1, 2015 22:29:43 GMT -5
agreed... but only for Afrezza!!!
|
|
|
Post by nylefty on Jun 1, 2015 22:49:46 GMT -5
I believe almost all investors would be smiling if $37/share target be reached by END of 2017. Does anyone have full report? I could not find the time frame (2017) for the $37 to be attained, not in those news articles --- there are a few places that were vague, maybe intentionally so. This is supposedly a direct quote from the Jefferies report: “Only a tenth of doctors screened had written an Afrezza script, we see MNKD’s efforts to expand access to spirometers and begin advertising in 3Q as key catalysts for uptake. With advertising, we expect the eventual rate of non-prescribers will fall closer to 12%. The 2015-2017 Afrezza use numbers implied by our survey suggests penetration rates nearly four times higher than we had previously modeled, and a $37 PT.”
But of course, MNKD won't be doing the advertising, Sanofi will.
|
|
|
Post by harryx1 on Jun 2, 2015 7:30:23 GMT -5
|
|
|
Post by kball on Jun 2, 2015 7:52:48 GMT -5
Could someone please get started making a "POPE HAT" for Harry when the Vegas meet up finally happens! Or perhaps Harry could just find one online?
|
|
|
Post by harryx1 on Jun 13, 2015 18:22:05 GMT -5
NEW YORK STATE DEPARTMENT OF HEALTH 06/12/2015 LIST OF MEDICAID REIMBURSABLE DRUGS www.emedny.org/info/fullform.pdfPage. 8 BND 00024-5882-36 3.08308 AFREZZA 30-4 UNIT + 60-8 UNIT G SANOFI-AVENTIS EA BND 00024-5874-90 2.50171 AFREZZA 4 UNITS CARTRIDGE INH G SANOFI-AVENTIS EA BND 00024-5884-63 2.79248 AFREZZA 60-4 UNIT + 30-8 UNIT G SANOFI-AVENTIS EA
|
|
|
Post by oscarlonzo on Jun 13, 2015 23:52:02 GMT -5
"NEW YORK STATE DEPARTMENT OF HEALTH 06/12/2015
LIST OF MEDICAID REIMBURSABLE DRUGS "
But you also need to pay attention to the codes. Next to afrezza is a "G":
"PA code "G" = PA required for Non Preferred drugs OR drugs not meeting clinical criteria (FQD, STEP) OR drugs in
Clinical Drug Review Program, the Brand Less than Generic Program or the Mandatory Generic Program"
Which basically means it's got the equivalent status of a tier 3 drug. Medicare has it that way and most likely all medicaid programs will as well.
|
|
|
Post by harryx1 on Jun 14, 2015 6:24:55 GMT -5
|
|
|
Post by daduke38 on Jun 14, 2015 11:55:54 GMT -5
After reading through this thread and the one titled "It's the Insurance Stupid" it seems to me that this is the real Hurdle. I have read some posts, but seeing it all together, it is overwhelming. Seems to me that this is where SNY really needs to do all they can. Even a knucklehead like me can see the long term savings of Afrezza. There was an example of Harvoni which I have personal experience with. I was covered and it only cost me $100.00 per month (not bad for a $90K treatment). But I was in late Stage 2. Ironically, my insurance has upped the co-pay since I was on it and it would now cost me about $5K out of pocket. Roughly 20 to 30% of people will never have liver damage due to HEP-C. Also, the liver can regenerate, so I can understand the Insurance Company's reluctance to pay if there is no advancement yet. And for what it's worth, Harvoni did cure me, and my liver is healing. But Afrezza is a different story. All the insurance companies see at this point is 2 less expensive alternatives. They aren't reading message boards, Twitter, Facebook etc. They are going by the stupid FDA studies, not several thousand real life experiences. I am an avid Chess player, and part of the game is to think ahead to not only what my next 10 moves may be, but also my opponents. Point of this is I try to think of why this is so heavily shorted, and again, being the knucklehead I am, I never thought of poor insurance coverage as a reason. I was told on YMB that I was considered an idiot over here, but I will post from time to time until Lianne blocks me I guess the thought is-------"IS insurance the big hurdle nobody want to talk about?"
|
|
|
Post by liane on Jun 14, 2015 12:00:53 GMT -5
I was told on YMB that I was considered an idiot over here, but I will post from time to time until Lianne blocks me I guess the thought is-------"IS insurance the big hurdle nobody want to talk about?" I think whoever said that on YMB is the idiot!
|
|
|
Post by harryx1 on Jun 14, 2015 12:13:11 GMT -5
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
XVIII. UTILIZATION MANAGEMENT—INSULINS P&T Comments A. Insulins: Inhaled Insulin (Afrezza)—PA Criteria Afrezza is rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with Type 1 or Type 2 diabetes mellitus. It is available as single-use cartridges of 4, 8, and 12 units, administered via oral inhalation at the beginning of a meal. Dosing must be individualized. Manual PA criteria were recommended to ensure appropriate use of the drug in Type 1 and Type 2 diabetic patients, including failure of or inability to tolerate an adequate trial (90 days) of a rapid or short-acting subcutaneous insulin product. The P&T Committee recommended (17 for, 0 opposed, 1 abstained, 0 absent) manual PA criteria for Afrezza, consistent with the FDA-approved product labeling for use in Type 1 and Type 2 diabetic patients. The full PA criteria are as follows: Manual PA criteria apply to all new and current users of Afrezza. Coverage is approved for non-smoking patients with either: Type 1 Diabetes Mellitus (diagnosed) 11 June 2015 Beneficiary Advisory Panel Background Information Page 19 of 20 • Failure to achieve hemoglobin A1C ≤ 7 % in 90 days of a rapid or shortacting subcutaneous (SC) insulin product or clinically significant adverse effects experienced with SC rapid or short-acting insulin unexpected to occur with inhaled insulin • Afrezza is used as adjunctive treatment to current basal insulin therapy • Spirometry testing [baseline forced expiratory volume in the first second (FEV1) upon initiation with repeated FEV1 at 6 months after initiation and repeated annually thereafter] has been performed Type 2 Diabetes Mellitus (diagnosed) • Failure to achieve hemoglobin A1C ≤ 7 % in 90 days of a rapid or short-acting SC insulin product or clinically significant adverse effects experienced with SC rapid or short-acting insulin unexpected to occur with inhaled insulin • Failure of or clinically significant adverse effect to two oral anti-diabetic agents [i.e. sulfonylurea, thiazolidinedione, or dipeptidyl peptidase-4 inhibitor] if metformin is contraindicated • Spirometry testing (baseline FEV1 upon initiation with repeated FEV1 at 6 months after initiation and repeated annually thereafter) has been performed Contraindications to the use of Afrezza: hypoglycemia, chronic lung disease (asthma, COPD), hypersensitivity to regular human insulin, or any Afrezza excipients XIX. UTILIZATION MANAGEMENT—INSULINS BAP Comments A. Insulins: Inhaled Insulin (Afrezza)—PA Criteria The P&T Committee’s recommendation for the Afrezza is listed above.
|
|
|
Post by yossarian on Jun 14, 2015 14:58:30 GMT -5
But looks like it will take a while before AFREZZA can be prescribed, i.e. at least a 90 day lag time. For Type 1 "• Failure to achieve hemoglobin A1C ≤ 7 % in 90 days of a rapid or shortacting subcutaneous (SC) insulin product or clinically significant adverse effects experienced with SC rapid or short-acting insulin unexpected to occur with inhaled insulin
For Type 2 "• Failure to achieve hemoglobin A1C ≤ 7 % in 90 days of a rapid or short-acting SC insulin product or clinically significant adverse effects experienced with SC rapid or short-acting insulin unexpected to occur with inhaled insulin"
|
|